A $100 million company growing every year on its sales team has proof it doesn't need marketing. Growth says the model works. It was never built to tell you what that model costs, what it can't reach, or what it can't survive. Three questions, all knowable, and nobody has gone looking.

Sycamore Partners' ~$10B Walgreens buyout didn't just change ownership, it split one company into five brands that each now have to earn their own commercial identity. Here's what that teardown reveals about the gap between operating strength and a buyer-ready story, and why it matters most for platforms far smaller than Walgreens. 

Impressive gets you the meeting. Enduring gets you paid. Most CEOs can't tell you which one they've actually built, until a buyer does it for them in diligence. Here's the question that separates the two, and why the pressure you're feeling right now might be the best sign you're close.

Six pilots with zero momentum isn't a growth problem. It's an orchestration problem — and it caps your multiple long before diligence begins. When sales, marketing, product, and ops each work in isolation, handoffs leak and pilots deplete the org instead of converting. A buyer sees that fragmentation as an unfinished system, and prices it accordingly.

Picture two healthcare companies at the negotiating table. Same earnings before interest, taxes, depreciation, and amortization (EBITDA). Same growth rate. Same category. One walks away with a premium multiple. The other gets a discounted offer wrapped in earnouts and conditions.

Every company eventually hits the point where what got it here won't get it there. The trouble is that growth disguises the moment, so most leaders miss it until a buyer, a board, or the market forces the question for them. Here's how to recognize it early, while you still hold the leverage.

Buyers evaluate risk before they ever consider opportunity. This article walks through the four lenses sophisticated acquirers apply to every healthcare company, and reveals why the gap between the valuation you expect and the offer you receive almost always lives in the lens you weren't watching. 

Buyers don't pay for conviction. They pay for conviction with proof behind it, and no two stories teach that lesson better than Ali Parsa's and Iman Abuzeid's.

Winning in Healthcare names a problem many healthcare leaders feel but few can explain: a company can grow revenue and build real momentum, and still watch its valuation fall behind.

Dr. Roxie Mooney argues that gap is rarely a growth problem. It is a structure, narrative, and transferability problem, and the most expensive issue a healthcare company can fail to see from the inside.

Today, Winning in Healthcare: How the Best Builders Turn Growth into Enterprise Value by our founder, Dr. Roxie Mooney, DBA, is officially available.

In the foreword, Mark Montgomery, former BioPlus Specialty Pharmacy CEO whose story closes the book, describes exactly what we set out to build:

"The next generation of healthcare leaders doesn't need another book about inspiration. They need a book about construction. How you build something real. How you make it scalable. How you make it something that can outlive you." — Mark Montgomery, Former CEO, BioPlus Specialty Pharmacy

A book about construction. That's precisely what this is.

Most healthcare companies don't fail because the idea was wrong. They fail because no one built the system required to survive success.

That line sits at the center of Winning in Healthcare: How the Best Builders Turn Growth Into Enterprise Value, releasing soon from Legacy DNA Press.

Revenue is up. The team is growing. The product works. By every visible measure, the business looks healthy.

But ask a buyer to look closely, and a different story often shows up.

Roughly 4 in 5 companies that hit product-market fit still fail to scale it. The difference comes down to whether the commercial system was ever built to carry the weight.